TIPS Procedure Contraindications: Absolute and Relative

A transjugular intrahepatic portosystemic shunt, commonly called TIPS, is one of the most effective procedures for relieving the dangerously high blood pressure inside the portal vein that drives many complications of liver cirrhosis. But not every patient with portal hypertension is a safe candidate. The procedure carries a defined set of absolute contraindications, where placing a shunt could be immediately life-threatening, and a longer list of relative contraindications that require careful weighing of risk against benefit. Understanding where those lines fall is critical, because the consequences of placing a TIPS in the wrong patient can be as severe as the condition it is meant to treat.

What TIPS Does and Why Contraindications Matter

TIPS works by creating a channel through the liver that connects the portal vein (carrying blood from the gut) to the hepatic vein (draining into the heart). This bypass lowers the pressure inside the portal system, which in turn reduces the risk of life-threatening variceal bleeding, helps clear stubborn ascites, and can even improve kidney function in certain patients with hepatorenal syndrome.¹ The procedure essentially reroutes a large volume of blood away from the liver and into the central circulation. That hemodynamic shift is the source of both its benefits and its dangers.

When blood that previously flowed through the liver is suddenly diverted, two things happen. First, the heart has to handle a surge in returning blood volume, with right atrial pressure rising by roughly 50 to 100 percent.² Second, the liver loses a portion of its blood supply, which can worsen liver function in patients whose livers are already failing. Every contraindication on the list traces back to one of these two consequences: the heart and lungs cannot tolerate the extra volume, or the liver cannot survive the lost blood flow.

Absolute Contraindications

Absolute contraindications are the hard stops. If any of these conditions is present, the procedure should not go forward regardless of how badly the patient needs portal pressure relief. A widely referenced categorization lists five:

Congestive heart failure: A heart already struggling to pump cannot absorb the sudden increase in blood volume that TIPS delivers. The result can be acute decompensation and pulmonary edema.
Severe pulmonary hypertension: When pressures in the lung vasculature are already dangerously high, the extra volume pushed through the right heart after TIPS can cause right-sided heart failure.
Multiple hepatic cysts: Polycystic liver disease fills the liver with fluid-filled sacs that leave no safe corridor for a shunt. Attempting to place one risks uncontrollable bleeding.
Uncontrolled systemic infection or sepsis: Placing a foreign body (the stent) in a patient with active bloodstream infection risks seeding the device and worsening sepsis.
Unrelieved biliary obstruction: If the bile ducts are blocked and the obstruction has not been addressed, the shunt tract risks crossing through dilated ducts, creating bile leaks and further complications.

These five conditions appear consistently across clinical guidelines.³ When clinicians describe a patient as “not a TIPS candidate,” one of these is usually the reason.

The Heart and Lungs Get the Closest Scrutiny

Cardiac and pulmonary contraindications receive outsized attention during pre-procedural workup because the hemodynamic consequences of getting them wrong are immediate. Coexisting portal hypertension and pulmonary hypertension or heart failure is considered a contraindication to TIPS precisely because the procedure’s intended effect, pushing more blood into the systemic circulation, is the last thing these patients need.⁴

This is why echocardiography before the procedure has become standard practice. A 15-year single-center analysis found that several measurements on a pre-TIPS echocardiogram predicted who would develop heart failure afterward. The estimated peak pulmonary artery systolic pressure performed best: at a cutoff of 31 mmHg, it caught about 70 percent of patients who went on to develop post-TIPS heart failure while correctly clearing 86 percent of those who did not.⁵ Enlarged right atrium size and left ventricular dimensions also flagged higher risk. The takeaway for patients is practical: if your care team orders an echocardiogram before discussing TIPS, it is not a formality. It is one of the strongest tools for deciding whether your heart can handle the procedure.

Relative Contraindications and the Gray Zone

Beyond the absolute stops, a range of relative contraindications make TIPS riskier but not automatically impossible. These are the situations where experienced teams weigh the individual patient’s circumstances. The same guideline that lists the absolute contraindications also names several relative ones: a severely elevated INR (above 5), very low platelet counts (below 20,000), moderate pulmonary hypertension, and portal vein thrombosis.⁶ Each of these raises the risk of procedural bleeding or poor outcomes but does not rule TIPS out in every case.

Active hepatic encephalopathy also falls into the relative category when TIPS is being considered electively. Because the shunt diverts portal blood, including gut-derived toxins like ammonia, away from the liver’s detoxifying capacity, it can trigger or worsen the confusion and impaired motor control that characterize encephalopathy. A patient already experiencing these symptoms is at higher risk of severe cognitive decline after the procedure. In emergency scenarios such as uncontrolled variceal bleeding, however, the calculus shifts: the immediate threat of death from hemorrhage may outweigh the risk of worsening encephalopathy.

Advanced Liver Failure and Scoring Thresholds

One of the trickiest judgment calls in TIPS candidacy involves patients whose liver disease is already very advanced. Severe hepatic failure and high baseline MELD scores have traditionally been treated as relative or absolute contraindications, because patients with the worst liver function often experience high post-TIPS mortality and rapid worsening of liver function after the procedure.⁷ The dilemma is that these are often the patients who need portal pressure relief most desperately.

Several scoring systems exist to help predict who will survive the procedure. The MELD score has been the workhorse, performing well as a short-term survival predictor with an accuracy metric (area under the curve) of about 0.72 for survival at one and three months after TIPS.⁸ A newer iteration, the MELD 3.0 score, outperformed the original MELD and MELD-Na at predicting three-month mortality in one study, with a score of 14 proposed as a threshold separating higher- from lower-risk patients.⁹ For longer-term prognosis, the MELD-Na variant and a newer tool called FIPS showed promise. None of these scores are perfect, but they give clinicians a structured way to quantify risk rather than relying on gut feeling alone.

The practical reality is that no single MELD cutoff is universally agreed upon as a line that should never be crossed. Centers with more experience in TIPS placement sometimes proceed at higher MELD values than less-experienced centers would attempt, provided the clinical situation justifies the risk. What matters for patients is that the team openly discusses where their liver function falls on these scales and what the numbers mean for likely outcomes.

Portal Vein Thrombosis, Once a Barrier, Now Mostly Manageable

Portal vein thrombosis deserves its own discussion because how clinicians think about it has changed substantially. A clot in the portal vein, and especially the formation of a portal cavernoma (a tangle of collateral vessels that develops when the main portal vein has been blocked for a long time), was once considered a relative contraindication because of the sheer technical difficulty of navigating a stent through or around the obstruction. Hitting the wrong collateral could cause dangerous bleeding.

Over the past decade, however, accumulating case reports and small patient series have demonstrated that TIPS is technically feasible in the vast majority of these patients and provides effective, long-term control of portal hypertension symptoms in cases that do not respond to standard treatment.¹⁰ The key qualifier is “experienced hands.” TIPS in the setting of chronic portal vein thrombosis remains technically demanding. If you are told you need TIPS but have portal vein thrombosis, a referral to a high-volume center with specific experience in these complex cases is worth pursuing.

Hepatic Encephalopathy After TIPS

Encephalopathy is not just a contraindication concern before the procedure; it is the primary adverse effect afterward, and it significantly limits the broader utility of TIPS. Symptoms range from mild confusion and personality changes to severe disorientation and loss of motor control. Post-TIPS encephalopathy is strongly linked to hospital readmission and diminished quality of life.¹¹

The underlying mechanism is straightforward: when portal blood bypasses the liver, ammonia and other toxins produced by gut bacteria reach the brain in higher concentrations. Strategies to manage this risk include careful preoperative assessment to identify patients most likely to develop encephalopathy, tailoring the shunt diameter to avoid diverting more blood than necessary, and sometimes embolizing spontaneous portosystemic shunts during the TIPS procedure itself. After the procedure, standard treatments like lactulose and rifaximin help reduce ammonia levels, and emerging approaches such as fecal microbiota transplantation are being explored. In refractory cases, the stent can be reduced in diameter or even occluded, essentially dialing back or undoing the shunt to restore more blood flow through the liver.

How Covered Stents Changed the Risk Profile

The technology used for TIPS has evolved in ways that bear directly on contraindication discussions. Early TIPS procedures used bare-metal stents, which had high rates of dysfunction as tissue grew into the stent and narrowed it over time. The introduction of polytetrafluoroethylene (PTFE)-covered stents dramatically improved outcomes. A meta-analysis of randomized controlled trials found that covered stents offered significantly better overall survival and shunt patency compared with bare stents.¹²

The difference is particularly striking in specific populations. In patients with Budd-Chiari syndrome (where hepatic veins are blocked), PTFE-covered stents maintained primary patency of about 67 percent at one year compared with just 19 percent for bare stents, and patients with covered stents needed far fewer repeat procedures to keep the shunt open.¹³ This matters for the contraindication conversation because some of the older literature on TIPS complications, including data on encephalopathy rates and shunt failure, comes from the bare-stent era. Outcomes today with covered stents are meaningfully better, and some patients who might have been considered poor candidates years ago may now be reasonable ones.

Preemptive TIPS in Emergency Bleeding

One of the most significant developments in TIPS practice is the concept of preemptive or “early” TIPS, placed within 24 to 72 hours of an acute variceal bleed rather than waiting for conventional treatment to fail. This approach has gained traction because of evidence that it improves outcomes in the highest-risk bleeders. In patients with the most advanced cirrhosis (Child-Pugh class C), preemptive TIPS was associated with one-year mortality of about 22 percent compared with roughly 47 percent for those treated with standard endoscopic banding and medications alone.¹⁴

The contraindication wrinkle here is that emergency settings compress the time available for the usual pre-procedural workup. A formal echocardiogram, full scoring assessment, and detailed vascular imaging are ideally performed before any TIPS, but when a patient is actively bleeding and at high risk of death, clinicians must sometimes make faster decisions with less information. The absolute contraindications still apply in emergencies: no amount of urgency justifies placing a TIPS in a patient with overt heart failure or sepsis. But some relative contraindications, like active encephalopathy or borderline hepatic reserve, may be weighed differently when the alternative is uncontrolled hemorrhage.

What Happens When TIPS Is Not an Option

For patients who are truly not candidates for TIPS, alternative procedures exist. Balloon-occluded retrograde transvenous obliteration, or BRTO, is one of the more important alternatives. BRTO works differently from TIPS: rather than creating a portal-to-systemic shunt, it obliterates the varices themselves by blocking the outflow vein and injecting a sclerosant. It is equally effective at controlling bleeding from gastric varices and is tolerated by patients with poor hepatic reserve who cannot handle the hemodynamic shifts of TIPS.¹⁵ BRTO has its own limitations, though: it does not lower portal pressure the way TIPS does, so it does not help with ascites or hepatorenal syndrome. The two procedures complement each other rather than competing, and the right choice depends on which complication is the primary problem.

For patients with recurrent ascites who cannot receive TIPS, large-volume paracentesis (draining fluid from the abdomen with a needle) remains the mainstay, though it treats symptoms rather than the underlying pressure problem. Liver transplantation, when available, addresses everything by replacing the diseased liver entirely, but wait times and candidacy requirements are their own separate set of hurdles.

TIPS in Children

Pediatric TIPS is uncommon and comes with its own set of considerations that go beyond the adult contraindication list. In children, TIPS is regarded as a temporary and technically demanding procedure.¹⁶ The smaller vessel sizes, growing anatomy, and different disease spectrum (children are more likely to have portal vein thrombosis from neonatal causes or metabolic liver diseases rather than alcohol-related cirrhosis) all add complexity. TIPS in pediatric patients is typically used as a bridge to transplant rather than a long-term solution, and the procedure is concentrated in a small number of specialized centers.

Kidney Function and Its Dual Role

The relationship between TIPS and kidney function illustrates how the same physiological change can be therapeutic for one patient and dangerous for another. When the shunt diverts blood into the systemic circulation, the increased cardiac output can improve renal perfusion. Studies have shown that fractional excretion of sodium increases in the weeks after TIPS, reflecting reduced activation of the hormonal system that causes the kidneys to retain salt and water aggressively in cirrhosis.¹⁷ This is why TIPS can be an effective treatment for hepatorenal syndrome, where the kidneys are shutting down because of the circulatory dysfunction caused by advanced liver disease.

But the same volume shift that helps the kidneys depends on the heart being able to handle it. In a patient whose heart is borderline, the surge in preload after TIPS may push the heart into failure, which then worsens kidney function rather than improving it. Pre-procedural assessment of both cardiac and renal function is therefore essential. A patient being evaluated for TIPS to treat hepatorenal syndrome needs careful cardiac screening precisely because the therapeutic mechanism and the potential harm share the same pathway: more blood reaching the central circulation.